Please assess the completion status of the following clinical trial:

Trial Title: Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis is laboratory-supported probable, probable, or definite according to the World Federation of Neurology El Escorial criteria~* Forced Vital Capacity (FVC) from 80 - 60% of predicted values at enrollment~* Bilateral phrenic nerve function acceptable as demonstrated by bilateral diaphragm EMG recordings and nerve conduction times without axonal lesion~Exclusion Criteria:~* Active cardiovascular disease that would increase the risk of general anesthesia. (FEVG\<60%)~* Underlying pulmonary diseases that were present prior to ALS that would effect pulmonary tests independent of ALS, in particular COPD with FEV1\<30%~* Pre-existing implanted electrical device such as a pacemaker or cardiac defibrillator~* respiratory infection or decompensation in the last 30 days~* Marked obesity affecting suitability for surgery~* Significant scoliosis or chest deformity affecting suitability for surgery~* Pre-existing diaphragm abnormality such as a hiatal hernia or paraesophageal hernia~* Patient on NIV, CPAP or Oxygen for a reason other than ALS~* Criteria for NIV (VC\<50% of predicted values and/or Pi max and SNIP\<60% of predicted values; and/or nocturnal desaturations without SAOS and/or PaCO2\>45 mm d'Hg)~* Supine VC\<50% of predicted values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- phenic nerve stimulation (Type: EXPERIMENTAL): effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
- sham (Type: SHAM_COMPARATOR): sham phenic nerve stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).